Auto-generated event page

Celldex Completes Enrollment in Global Phase 3 Studies (EMBARQ-CSU1 and EMBARQ-CSU2) of Barzolvolimab in Chronic Spontaneous Urticaria

HAMPTON, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today the completion of enrollment in the Company’s global Phase 3 program of barzolvolimab in c...

Score 41 low confidence 1 source posts Updated Feb 25, 2026, 12:16 PM UTC

Track This Event Open Event in App More Signal Pages

Cluster sources

Newest source rows first.

Celldex Completes Enrollment in Global Phase 3 Studies (EMBARQ-CSU1 and EMBARQ-CSU2) of Barzolvolimab in Chronic Spontaneous Urticaria

GlobeNewswire Public Companies • Feb 25, 2026, 12:01 PM UTC

Entity focus

Direct link to post

https://pushme.site/signals/135551-celldex-completes-enrollment-in-global-phase-3-studies-embarq-csu1-and-e?utm_source=signal-135551&utm_medium=social&utm_campaign=signal-pages&utm_content=hero

Quick distribution loop

Step 1

Post this live link in threads where users ask how to monitor this event.

Step 2

Point readers to "Track This Event" for immediate conversion into an alert.

Step 3

Reuse entity keywords from this page for targeted follow-up replies.

Back to signal pages Open query hub